Abstract
The aim of the study was to investigate the safety and anti-inflammatory effects of polysaccharide fraction (F1) of Curcuma longa extract (NR-INF-02) in classical rodent models of inflammation. F1 was evaluated for its acute oral toxicity and found to be safe upto 5000 mg/kg body weight in rats. The anti-inflammatory activity of F1 was evaluated in acute (carrageenan - induced paw edema; xylene - induced ear edema) and chronic (cotton pellet - induced granuloma) models of inflammation. The results of the study demonstrated that F1 significantly (p ≤ 0.05) inhibited carrageenan-induced paw edema at 1 h and 3 h at doses of 11.25, 22.5 and 45 mg/kg body weight in rats. Also, F1 at doses of 15.75, 31.5 and 63 mg/kg significantly inhibited the xylene induced ear edema in mice. In a chronic model, F1 at 11.25, 22.5 and 45 mg/kg doses produced significant reduction of wet and dry weights of cotton pellets in rats. Overall results indicated that F1 of NR-INF-02 significantly attenuated acute and chronic inflammation in rodent models. This study emphasizes on the importance of Curcuma longa polysaccharide’s role in acute and chronic inflammation.
Keywords: Anti-inflammatory, Curcuma longa, NR-INF-02, Polysaccharide fraction.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Anti-Inflammatory Activity of Polysaccharide Fraction of Curcuma longa Extract (NR-INF-02)
Volume: 14 Issue: 1
Author(s): Ramanaiah Illuri, Bharathi Bethapudi, Senthilkumar Anandakumar, Sasikumar Murugan, Joshua A. Joseph, Deepak Mundkinajeddu, Amit Agarwal and Chandrasekaran C.V.
Affiliation:
Keywords: Anti-inflammatory, Curcuma longa, NR-INF-02, Polysaccharide fraction.
Abstract: The aim of the study was to investigate the safety and anti-inflammatory effects of polysaccharide fraction (F1) of Curcuma longa extract (NR-INF-02) in classical rodent models of inflammation. F1 was evaluated for its acute oral toxicity and found to be safe upto 5000 mg/kg body weight in rats. The anti-inflammatory activity of F1 was evaluated in acute (carrageenan - induced paw edema; xylene - induced ear edema) and chronic (cotton pellet - induced granuloma) models of inflammation. The results of the study demonstrated that F1 significantly (p ≤ 0.05) inhibited carrageenan-induced paw edema at 1 h and 3 h at doses of 11.25, 22.5 and 45 mg/kg body weight in rats. Also, F1 at doses of 15.75, 31.5 and 63 mg/kg significantly inhibited the xylene induced ear edema in mice. In a chronic model, F1 at 11.25, 22.5 and 45 mg/kg doses produced significant reduction of wet and dry weights of cotton pellets in rats. Overall results indicated that F1 of NR-INF-02 significantly attenuated acute and chronic inflammation in rodent models. This study emphasizes on the importance of Curcuma longa polysaccharide’s role in acute and chronic inflammation.
Export Options
About this article
Cite this article as:
Illuri Ramanaiah, Bethapudi Bharathi, Anandakumar Senthilkumar, Murugan Sasikumar, Joseph A. Joshua, Mundkinajeddu Deepak, Agarwal Amit and C.V. Chandrasekaran, Anti-Inflammatory Activity of Polysaccharide Fraction of Curcuma longa Extract (NR-INF-02), Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2015; 14 (1) . https://dx.doi.org/10.2174/1871523014666150407150533
DOI https://dx.doi.org/10.2174/1871523014666150407150533 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Acute Respiratory Failure in Obstetric Patients
Current Women`s Health Reviews Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews Metabolism-based Drug-drug Interactions in Patients with Chronic Respiratory Diseases: A Review Focusing on Drugs Affecting the Respiratory System
Current Drug Metabolism The Evil Axis of Obesity, Inflammation and Type-2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Open Source Tools and Resources in Virtual Screening for Drug Discovery
Combinatorial Chemistry & High Throughput Screening Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Synthetic Aspects and First-time Assessment of 2-amino-1,3-selenazoles Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery Dietary Habits of Mongolian People, and Their Influence on Lifestyle-Related Diseases and Early Aging
Current Aging Science Vitamin D and Metabolic Syndrome: Is There a Link?
Current Pharmaceutical Design Anti-Inflammatory and Antioxidant Properties of Piper Species: A Perspective from Screening to Molecular Mechanisms
Current Topics in Medicinal Chemistry Hypocholesterolemia
Current Vascular Pharmacology The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design Synthesis and Antioxidant Activity of 1,2,4-Triazole linked Thieno[2,3- d]pyrimidine Derivatives
Letters in Drug Design & Discovery Cardiac Morbidity in an HIV-1 Lipodystrophy Patient Cohort Expressing the TNF-α-238 G/A Single Nucleotide Gene Polymorphism
Current HIV Research Managing the Liabilities Arising from Structural Alerts: A Safe Philosophy for Medicinal Chemists
Current Medicinal Chemistry Biological Activities of Quinoline Derivatives
Mini-Reviews in Medicinal Chemistry TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
Current Cancer Drug Targets Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
CNS & Neurological Disorders - Drug Targets